Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in
the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has
been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and
nasopharyngeal cancer in different countries. The Clinical efficacy has been shown in adult
with head and neck cancer. The study assessed the clinical efficacy, and safety of the
combination of Nimotuzumab administered concomitantly with chemotherapy and radiotherapy in
patients with advanced nasopharyngeal cancer.